

CITATION REPORT

List of articles citing

Phosphodiesterase inhibitors and the eye

DOI: 10.1111/j.1442-9071.2009.02070.x

Clinical and Experimental Ophthalmology, 2009, 37, 514-23.

Source: <https://exaly.com/paper-pdf/45872984/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
40	Role of nitric oxide in the regulation of intraocular pressure: a possibility for glaucoma treatment. <i>Expert Review of Ophthalmology</i> , 2010 , 5, 751-758	1.5	1
39	Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment. <i>Current Opinion in Pharmacology</i> , 2011 , 11, 689-97	5.1	32
38	Identification of amino acid residues responsible for the selectivity of tadalafil binding to two closely related phosphodiesterases, PDE5 and PDE6. <i>Journal of Biological Chemistry</i> , 2012 , 287, 41406-16	5.4	26
37	Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension. <i>BMJ, The</i> , 2012 , 344, e554	5.9	34
36	The effects of moxaverine on ocular blood flow in patients with age-related macular degeneration or primary open angle glaucoma and in healthy control subjects. <i>Acta Ophthalmologica</i> , 2012 , 90, 139-45	3.7	18
35	Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013 , 9, 1193-205	5.5	19
34	Central serous chorioretinopathy: a review of epidemiology and pathophysiology. <i>Clinical and Experimental Ophthalmology</i> , 2013 , 41, 201-14	2.4	226
33	Curcumin analogues inhibit phosphodiesterase-5 and dilate rat pulmonary arteries. <i>Journal of Pharmacy and Pharmacology</i> , 2015 , 67, 87-95	4.8	14
32	Acute macular edema following intracorporeal prostaglandin injection for erectile dysfunction. <i>International Medical Case Reports Journal</i> , 2015 , 8, 141-4	1	3
31	[Recently recognized ophthalmic complications of systemic treatments]. <i>Journal Francais D'Ophtalmologie</i> , 2015 , 38, 876-82	0.8	4
30	Toxic optic neuropathies: an updated review. <i>Acta Ophthalmologica</i> , 2015 , 93, 402-10	3.7	93
29	Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction. <i>Drug Design, Development and Therapy</i> , 2016 , 8, 3407-3413	4.4	21
28	Ocular perfusion pressure and color Doppler imaging of the external ophthalmic artery of rabbits treated with sildenafil citrate. <i>BMC Veterinary Research</i> , 2016 , 12, 149	2.7	1
27	Strategies and Assays for Minimizing Risk of Ocular Toxicity During Early Development of Systemically Administered Drugs. 2016 , 201-213		
26	The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 141-52	4.1	35
25	Ocular Applications of Dipyridamole: A Review of Indications and Routes of Administration. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2016 , 32, 83-9	2.6	2
24	Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2017 , 32, 311-330	5.6	20

23	Effects of Root Extracts of Eurycoma longifolia Jack on Corpus Cavernosum of Rat. <i>Medical Principles and Practice</i> , 2017 , 26, 258-265	2.1	2
22	An immunohistochemical and ultrastructural analysis of the retina in tadalafil (Cialis) treated rats. <i>Acta Histochemica</i> , 2018 , 120, 312-322	2	1
21	Design and synthesis of novel annulated thienopyrimidines as phosphodiesterase 5 (PDE5) inhibitors. <i>Archiv Der Pharmazie</i> , 2018 , 351, e1800018	4.3	7
20	Electrophysiological determination of phosphodiesterase-6 inhibitor inhibition constants in intact mouse retina. <i>Toxicology and Applied Pharmacology</i> , 2018 , 345, 57-65	4.6	4
19	An update on the drug safety of treating erectile dysfunction. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 965-975	4.1	6
18	Precautions and Monitoring of Patients Taking Phosphodiesterase Type 5 Inhibitors Who are at Risk of Increased Intraocular Pressure. <i>Drugs and Aging</i> , 2019 , 36, 991-997	4.7	3
17	Naringin protects against Bisphenol-A induced oculopathy as implication of cataract in hypertensive rat model. <i>Biomedicine and Pharmacotherapy</i> , 2020 , 126, 110043	7.5	7
16	Erythroptosis and Chromatopsia: Case Study and Brief Review. <i>Neuro-Ophthalmology</i> , 2021 , 45, 56-60	0.9	0
15	Visual Side Effects Linked to Sildenafil Consumption: An Update. <i>Biomedicines</i> , 2021 , 9,	4.8	3
14	Photoreceptor phosphodiesterase (PDE6): activation and inactivation mechanisms during visual transduction in rods and cones. <i>Pflugers Archiv European Journal of Physiology</i> , 2021 , 473, 1377-1391	4.6	2
13	Sildenafil in ophthalmology: An update. <i>Survey of Ophthalmology</i> , 2021 ,	6.1	3
12	Glaucoma Clinical Research: Trends in Treatment Strategies and Drug Development. <i>Frontiers in Medicine</i> , 2021 , 8, 733080	4.9	4
11	Bilateral neurosensory retinal detachment secondary to tadalafil treatment. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2021 ,	0.5	
10	Effect of periodic sildenafil dosage on intraocular pressure in patients with erectile dysfunction. <i>Electronic Physician</i> , 2017 , 9, 5229-5232	1.8	4
9	[Drug-induced toxic optic neuropathy]. 2020 , 136, 156-164		2
8	Bilateral neurosensory retinal detachment secondary to tadalafil treatment.. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2022 , 97, 234-238	0.1	1
7	Photoreceptor Phosphodiesterase (PDE6): Structure, Regulatory Mechanisms, and Implications for Treatment of Retinal Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2021 ,	3.6	2
6	Risk of Ocular Adverse Events Associated With Use of Phosphodiesterase 5 Inhibitors in Men in the US.. <i>JAMA Ophthalmology</i> , 2022 ,	3.9	1

- 5 Effect of cAMP and cGMP on Connexin43 Expression in Isolated Human and Bovine Ciliary Epithelium. *American Journal of Molecular Biology*, **2022**, 12, 97-108 0.2
- 4 Case report: Bilateral central serous chorioretinopathy-like abnormalities in a man with pulmonary arterial hypertension. 9,
- 3 Use of Visual Electrophysiology to Monitor Retinal and Optic Nerve Toxicity of Medications. **2022**, 12, 1390 0
- 2 Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders. **2023**, 63, 1
- 1 A Review on the Pharmacological Importance of PDE5 and Its Inhibition to Manage Biomedical Conditions. 0976500X2211290 0